Breaks Categories: Stock Spotlights

ThursdayJan 19, 2017 11:56 am

NetworkNewsBreaks – CV Sciences, Inc. (CVSI) Mines the Benefits of Science and Nature to Build Cannabidiol-Based Portfolio

The strategic integration of science and nature is the cornerstone of operations at CV Sciences (OTCQB: CVSI). Its Pharmaceuticals Division, for example, is developing synthetically formulated cannabidiol (CBD)‐based medicine for which the company is pursuing FDA approval. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for the treatment of a range of medical conditions. The company’s initial drug candidate (CVSI-007) is a chewing gum containing nicotine and synthetic CBD to support cessation of smokeless tobacco use and addiction. Focusing on enhancing the quality of life, CV Sciences’ Consumer Products Division delivers botanical-based CBD products such…

Continue Reading

ThursdayJan 19, 2017 11:48 am

NetworkNewsBreaks – Rosetta Genomics Ltd. (NASDAQ: ROSG) Sets Stage for Value Creation in 2017

Rosetta Genomics (NASDAQ: ROSG) is an international company leveraging a growing IP portfolio to develop and commercialize microRNA-based and other molecular diagnostic programs in cancer and various other indications. In 2016, Rosetta was primarily focused on the commercial launch of its Reveal assay for the classification of indeterminate thyroid nodules, and it signed an exclusive distribution agreement with Rhenium Ltd. for the sales and marketing of Reveal in Israel. In a December earnings release, Rosetta Genomics said it expects FY2017 RosettaGX Reveal revenue to be between $4 million and $5 million. The company is also advancing a number of other…

Continue Reading

WednesdayJan 18, 2017 1:25 pm

NetworkNewsBreaks – aTyr’s (NASDAQ: LIFE) Resolaris™ Obtains Fast Track Designation from FDA, Partial Clinical Hold Removed

Shares of aTyr Pharma (NASDAQ: LIFE) climbed more than 25% in mid-day trade following news that the company’s Resolaris™ candidate was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy 2B, making it the first known therapeutic candidate to receive the designation for this treatment. The FDA also removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials, providing dosing flexibility moving forward. "This Fast Track designation, which is granted to drug candidates addressing serious conditions and that demonstrate the potential to address unmet medical…

Continue Reading

TuesdayJan 17, 2017 3:50 pm

NetworkNewsBreaks – Veru Healthcare (NASDAQ: FHCO) Continues Rally on Launch of OTC Premature Ejaculation Product

Shares of Veru Healthcare (NASDAQ: FHCO) are higher in Monday trade, moving on momentum from the recent launch of the company's proprietary, over-the-counter PREBOOST® product to help prevent premature ejaculation (PE). As the only individually packaged medicated wipe that contains a desensitizing agent (4% benzocaine), PREBOOST allows for discrete, direct and precise dosage with each use. Top line results from an independent clinical study of PREBOOST show that men treated with PREBOOST had statistically significant improvement in their ability to control ejaculation, while 80% were no longer considered to have PE. The intended reach of PREBOOST is two-fold. On one…

Continue Reading

TuesdayJan 17, 2017 1:18 pm

NetworkNewsBreaks – Benitec (NASDAQ: BNTC) Shares Surge on Orphan Drug Designation for BB-301 in the EU

Benitec Biopharma (NASDAQ: BNTC; BNTCW) is trading 71% higher on news that the company’s BB-301 for the treatment of patients with oculopharyngeal muscular dystrophy (OPMD) has been granted Orphan Drug Designation by the European Commission. The designation, which provides regulatory and financial incentives including a 10-year period of marketing exclusivity in the EU after product approval and protocol assistance from the European Medicines Agency (EMA) during the product development phase, was based on favorable recommendation from the EMA Committee for Orphan Medicinal Products (COMP). Entry into the clinic with a phase I/II study in OPMD patients is anticipated in 2018,…

Continue Reading

TuesdayJan 17, 2017 9:17 am

NetworkNewsBreaks – Amyris, Inc. (NASDAQ: AMRS) Making Technological Breakthroughs under Guidance of Highly Experienced Management

Amyris (NASDAQ: AMRS) is one of the fastest growing industrial biotechnology companies among the 2,772 in the U.S today. The company's eight-person management team is comprised of hand-picked individuals with a proven ability to innovate and build companies in a number of industries. With over 30 years of experience as a tech entrepreneur and thought leader, president and CEO John Melo has led Amyris from technology development and industrial startup to product development and final commercialization. Thanks to the team's level of experience, Amyris has made outstanding technological breakthroughs, among these is the world's leading treatment for malaria, saving over…

Continue Reading

FridayJan 13, 2017 2:09 pm

NetworkNewsBreaks – Medical Transcription Billing, Corp. (NASDAQ: MTBC) Embraces Possible Obamacare Changes in Trump Presidency

Medical Transcription Billing (NASDAQ: MTBC) (NASDAQ: MTBCP) offers services that could actually become more sought-after following changes to health insurance laws. “There are concerns that if the Trump administration completely repeals Obamacare, this might remove the need for a series of services currently offered by healthcare technology companies, such as revenue cycle management or more comprehensive practice management solutions.” … “Medical Transcription Billing believes the exact opposite. The company’s management feels that it is very unlikely that the Trump administration and the Republican-led Congress will completely eliminate insurance for 25 million Americans. The more likely scenario is that the administration…

Continue Reading

FridayJan 13, 2017 2:03 pm

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Remains Steady in Position as O2O Service Leader; Anticipates Revenue Boost with Xinhua Game Channel

Moxian, Inc. (NASDAQ: MOXC) continues to position itself as a leader in the O2O service market and a competitive digital marketing company in China by presenting new platforms. “Launched as a joint effort with Xinhua New Media and aimed at further strengthening the company’s partnership with Xinhua New Media Culture Communication Co., Ltd., the game channel is expected to bring multiple benefits to the company, including higher revenue streams from advertisement sales and game downloads, as well as ultimately attracting new users for its own Moxian+ platform and app. The project can bring massive exposure to the company’s services, given…

Continue Reading

FridayJan 13, 2017 1:58 pm

NetworkNewsBreaks – Naked Brand Group, Inc. (NASDAQ: NAKD) Shares Skyrocket on LOI to Merge with Bendon Limited

Shares of Naked Brand Group (NASDAQ: NAKD) soared 173% following this morning’s announcement that the company has entered into a letter of intent for a proposed merger with Bendon Limited to create a portfolio of innerwear, sleepwear and swimwear brands. Per the agreement, Bendon gains immediate access to the U.S. market while Naked will be able to leverage Bendon’s well-established global distribution channels. Naked CEO Carol Hochman will serve as COO of the emerging company. “We are extremely excited about the potential of this proposed merger, and look forward to capitalizing on Bendon’s scale and expertise to further expand the…

Continue Reading

ThursdayJan 12, 2017 2:16 pm

NetworkNewsBreaks – Transgenomic, Inc. (NASDAQ: TBIO) Shares Skyrocket on Licensing Deal with LifeLabs for ICE COLD-PCR, Canadian Patent Allowance

Shares of Transgenomic (NASDAQ: TBIO) are up roughly 169% late morning on word of its licensing agreement with Canadian laboratory service provider LifeLabs, which will use Transgenomics’ ICE COLD-PCR (ICP) technology as its mutation enrichment platform for cancer testing. The three-year renewable agreement permits LifeLabs to benefit from technology improvements and additional product launches during its term. Separately, Transgenomic also announced issuance of a new Canadian patent for ICP which covers the use of the ICE COLD-PCR method that enriches mutated DNA sequences in a background of normal DNA through to 2030. “We believe that this sizable commercial licensing agreement…

Continue Reading